Clinical Trial Update: The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy [Phase 3]

View source ↗

Summary

Phase 3 trial of ART-123 in sepsis and coagulopathy was withdrawn from status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coagulopathy
• Sepsis

Drugs mentioned

• ART-123 (recombinant human soluble thrombomodulin)

Snippet

Sponsor: Asahi Kasei Pharma America Corporation | Conditions: Sepsis and Coagulopathy | Phase 3 | Status: WITHDRAWN